Growth medium for primary pancreatic tumor cell culture
Patent 6087174 Issued on July 11, 2000. Estimated Expiration Date: March 18, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/405, Contains a growth factor or growth regulator435/384, Culture medium contains a growth factor or growth regulator435/387, Medium contains a polypeptide hormone435/391, Culture medium contains an animal extract435/392, Serum435/404, Culture medium, per se435/406, Contains a polypeptide hormone435/408Contains an animal extract
The present invention provides a method of treating cancer comprising (a) obtaining a tumor cell line, (b) modifying the tumor cell line to render it capable of producing an increased level of a cytokine relative to the unmodified tumor cell line, and (c) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained, wherein the tumor cell line is allogeneic and is not MHC-matched to the host. The present invention also provides a pancreatic tumor cell line, a method and medium for obtaining such a tumor cell line, and a composition comprised of cells of a purified pancreatic tumor cell line.
Other References
Maurer et al Animal Cell Culture: A Practical Approach, Chapter 2, IRL Press 13-19, 1986
van Valen et al Cancer Research Clin Oncol vol. 118(4): 269, 1992
Sinclair et al Blood vol. 72(1):66-72, Jul. 1988
Darrow et al., J. Immunol., 142, 3329-3335 (1989)
Gastl et al., Cancer research, 52, 6229-6236 (1992)
Golumbek et al., Cancer Research, 53, 5841-5844 (1993)
Hom et al., J. Immunother., 10, 153-164 (1991)
Huang et al., Science, 264, 961-965 (1994)
Itaya et al., Cancer Research, 47, 3136-3140 (1987)
Jaffee et al., Cancer Research, 53, 2221-2226 (1993)
Jaffee et al., Seminars in Oncology, 22, 81-91 (1995)
Kalthoff et al., Contrib. Oncol., 50, 101-110 (1995)
Kawakami et al., J. Immunol., 148, 638-643 (1992)
Nabel et al., Proc. Natl. Acad. Sci. USA, 90, 11307-11311 (1993)
Ostrand-Rosenberg et al., Int. J. Cancer: Supplement, 6, 61-68 (1991)
Plautz et al., Proc. Natl. Acad. Sci. USA, 90, 4645-4649 (1993)
Szuromi (ed.), Science, 264, 885 (1994)
Database WPI, Week 7808, Derwent Info Ltd., AN 77-09702Y/06 (JP 53-003-509 abstract). (Jan. 13, 1978)
Database WPI, Week 8928, Derwent Info Ltd., AN 89-206442/28 (WO 89/05631 abstract). (Jun. 29, 1989)
Database WPI, Week 9035, Derwent Info Ltd., AN 90-266194/35 (JP 2-188-532 abstract). (Jul. 24, 1990)
Database WPI, Week 9250, Derwent Info Ltd., AN 92-415476/50 (WO 92/20374 abstract). (Nov. 26, 1992)
Database WPI, Week 9317, Derwent Info Ltd., AN 93-136183/17 (EP 538,952 abstract). (Apr. 28, 1993)
Database WPI, Week 9432 and 9518, Derwent Info Ltd., AN 94-264105/32 (WO 94/17192 abstract). (Aug. 4, 1994)
Database WPI, Week 9503, Derwent Info Ltd., AN 95-022468/03 (WO 94/27635 abstract). (Dec. 8, 1994)
Database WPI, Week 9536, Derwent Info Ltd., AN 94-169430/21 (EP 599,077 abstract). (Nov. 23, 1994